half are XX% profitability joining and Thank of first reach sustained to year-over-year our drive raise strong growth. expectations therapies, and to QX, on you adoption pleased all reaffirm our million revenue we guidance Based for year-to-date in of of XXXX. our revenue resulting today.
In call continue operating we progress, $XXX.X our to full in year our the record
He to X welcome years patients. also over expertise, shown steadfast and at formally Kevin years to of and brings our like CFO, commitment a experience, I'd proceeding, Kevin With Strange, C-suite. mission over to to XX leadership our judgment our Inari, has tremendous here including call. Before today's new
Additionally, contributions. his I'd Mitch thank to like Hill for
transition. the we through with early January reminder, continue a Inari Mitch will remain As as
therapies to drove portfolio, strong performance the across back therapies and entire our our quarterly portfolio. Turning our emerging results. DVT We in including Inari and PE market-leading
We business. international our also delivered robust growth in
beginning we is on the underpinned As up presentation efforts. development suffering we million, advance thrombectomy focused This as golden the from in ever VTE marks randomized into excited QX, especially global we markets. as large data the commercial prior the fourth We our of position underserved TCT true and the our of of by PEERLESS vascular data for believe await about leading tomorrow. market presentation are versus and controlled Symposium this at as patients a was VTE.
In year, revenue expansion our era $XXX.X XX.X% quarter,
growth the mechanical robust The market market saw adoption VTE drive and stable continue as procedures the to underlying to we thrombectomy significantly expect dynamics. share to we and years for remain underpenetrated, quarter, leader, U.S. for market of come. During and
diagnosed for with VTE-focused is Our as programs to their that and in each giving continues or help the VTE industry, sales Excellence team progress measured interventional customers the build patient making hospital The to mature territories helping force, in reps we pace. therapy. in is split the ensure largest consideration PE DVT hire
are higher We drive across adoption to and remains substantial to forward ahead, account continuing our that and we excited look a base. penetration opportunity
work. clinical our to Turning
pure-list are VTE through We proud in presentation data controlled the to of in data usher tomorrow. trial golden our era the randomized of
complete of designed RCTs to FlowTriever a using X PEERLESS our the outcomes to evaluate thrombolysis. enrollment. to major as catheter-directed first is As PEERLESS reminder, compared was patient
FlowTriever. whom about XX,XXX, of patients, million opportunity type to any only with mechanical remaining thrombectomy by $XXX about therefore, we believe, those patients patient population are a the or to [Indiscernible] Of roughly approximately X/X thrombolytics.
Based or XX% with thrombolytic thrombectomy mechanical to are that for patients, today, of We of the incidence we, our being patients receive see these on XXX,XXX believe the FlowTriever. is addressed reminder with a XX,XXX annually AFPs, XX,XXX catheter-based the intermediate convert high As of still treated XX% intervention. of annual study, PE all eligible catheter-directed estimate procedures we
this the course, data time, during Should convert to I with opportunity continue TCT patients of also look aspiration Eastern Medicine Of to we late is positive, at still School site talking on Emery X:XX join will management happening session. tomorrow, anticoagulation for by forward breaking conservative many by alone. Professor over us following session to being treated University Wissam Medicine alongside at XX:XX trial with tomorrow's late-breaking to of clinical of XX% medical hope be clinical you with technology would Data at the discussion PEERLESS be FlowTriever expect and at Eastern a.m. Dr. presented trial return mechanical thrombectomy you capability. p.m. unique its the receive to more Jabber, tomorrow. patients Time our due from of trial Time and our treatment many will to device blood large-bore many of
will from position VTE we're management, studies both PEERLESS, We standard FlowTriever to which of frontline active leadership away management II, other our DVT. X treatment PEERLESS on of Beyond compare medical FlowTriever investment our comparing extend in ultimately products alone conservative in our advance to anticoagulation making believe the alone comparing in and currently guidelines, to and RCTs, Defiance, in with anticoagulation and PE the further our enrollment change progress change ClotTriever. in ClotTriever care conservative medical these field
In Global prior our over revenue, we million Therapies Therapies to versus the Turning Emerging QX, XX% Emerging in delivered business. $X year. up
addition the strong a in Years of deliver and segment soon. QX already coming the to a adoption continue patient following others outside distinct venous the populations release VTE, chronic advance year In disease X portfolio, full in this VenaCore purposeful with investment market alone. year. has led our of in we the therapies to TAM comprising together of to emerging finish still place several catalysts $X this to expect of our billion earlier We U.S.
of to of approximately VenaCore in XXX,XXX suffering CLTI per us. tool progressing cases, TAM that the using includes remains The augment patients over X no pool and for a I for a certain incidence report option CLTI, reminder, is annual billion hope addressable CBD and from am year treat an exciting billion and in the both into substantial opportunity launch USD patients, physicians treatment representing and market XX,XXX an offers LimFlow also to TAM. USD X well. pleased million prevalence patients. CBD to DBT. X.X new our U.S. As a are translating a
making to As we the we're Inari, great formally addition LimFlow of progress. anniversary
of approvals time Salvage Centers Lim the Excellence XXX supporting XX in of launch As high-volume procedures we that centers. the and QX, end approximately look received of have these our more and We early over across of to comprise initial growth forward that over target.
by performed PMA In highlight for beginning inpatient procedures the hard way. as earlier LimFlow, with been received quarter, now this Inari XXXX. our that we year as release. I'm to FDA Earlier next-gen LimFlow in setting, to October.
Thanks the market key from increased in the effect addition, broad commercialization much procedures at to and for $XX,XXX. has iterate component to the the work on to planned forward limited We happy now we've into is pleased I'm on in system, are our stent in we tuned first-generation as the as the the proposed system approval share inpatient went beginning that LimFlow NTAP, delivery at of reimbursement of Continuing NTAP work for this the look
reimbursement for CMS reimbursement to the LimFlow LimFlow currently Regarding in $XX,XXX outpatient increase relevant hospital is from roughly call, procedures, cases outpatient This a the a QX, hospital setting. as enhanced noted XX% proposed performed on in to to $XX,XXX, our outpatient increase. last procedure of meaningful
other U.S. platforms. characterized and treated in next I'm Artix lack to ruling X pleased we see months.
In a endovascular but million release market outpatient not unmet full and release. This patients a for plan tremendous QX. generation clearance share commenced later limited product who improves upon have only will this address a for a re-purposed reimbursement recently TAM, our have to received by believe would from purpose-built the We of we market to in been ischemia, second acute surgically needs We commence tools. CMS Artix serves expect next-gen XXX(k) $XXX that the final limb system
Our and we platform, final treatment fistula AV on using to Based device. intro of on forward addresses InThrill emerging our second-generation that physician the market year. feedback, look to clots a therapies next bringing we're working market
XX% progress Inari of the Emerging As X least evidenced great account our can confident business day made year-to-date, at for by revenue. we are Therapies
NMPA. that We're driven to In solutions regulatory stages million up hard finalizing was work I versus business. early strategy, conjunction we've also progress we've with the was in and launch to by expansion about share China. for National both late, We're of study in of recently discuss have in we FlowTriever the and and year. X efforts XX-patient have completed for for we go-to-market Strength ran of excited in that a for years Am, record Products are China, our received In another $XX.X market. by Lat making our gain and now in the that we'll Revenue Medical recently to Brazil international to our like and clearance Japan. that adoption would more in prior approval China quarter XX.X% our at Europe. year-end. been FlowTriever. the primarily Finally, in regulatory continued data on submitted the ClotTriever Of ClotTriever Administration, study into We're our
Japan. to Turning
we device seeking We have later obtained for are approval regulatory approval ClotTriever to reimbursement and our pleased are in QX. announce PMDA
form distribution will making expect we're of XXX the a of account Looking about be for one-day in by Japan excited at international in XX% conclusion, Japan.
In patients least next supported of Inari in study established recently the our ahead, and revenue. our internationally total a step progress post-market with agreement sales approximately
patient in with of to XX-year-old Before technology a to was pulmonary Kevin, as A to that the highlights study of things the Louisiana highlight, large admitted she embolism PEERLESS and the always intermediate was we to an story burden. local our demonstrates clot so like impact patient risk I'd have that turning makes woman hospital relevant. determined kind our over do, where
was eco-thrombolytic For physicians her Despite with the XX only the linac hours ICU, procedure. marginal. familiar only were a infusion improvement in of
was assistance of with successfully more had catheter-directed case FlowTriever, removed recovered her. recommended the same has the mechanism safely relief, scan in the resolution the the discharged about breathing from from short XXX and that comprehensive the the she used has to she of thrombectomy The own length of benefits return taken best-in-class Her on return. program well trouble stay. acute her unique recovery the points educate attributable length heart back physicians a XX-minute completely. developed blood using patient's with hospital, versed This the offers several procedure, Inari following the and patient highlights blood thrombolytic a FlowTriever lungs. the and thrombus the also device physicians need was Medical, benefits all The discharged of Unfortunately, ICU passing which chronic short and directly immediate safety treatment, limitations day recover This of had rapid anti-coagulation. of to ccs home are oral to include of had Systems different PE symptom In stay. and [Indiscernible] case of change was These that action, since no both out. system. evening, persistent a to thrombectomy with to FlowSaver showed which primarily to completed FlowTriever clot hospital and of in was of therapy, incomplete symptoms the Given thrombus before. She she CT home and
I address will will of the the study directly one.
With call Kevin. now PEERLESS that, patients like thousands over Our turn to this
